ArticleAnnals of neurology2025
Volumetric MRI Comparing Longitudinal Change in MOGAD to NMOSD, MS and Healthy Controls, and Disability Associations.
Article in Annals of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Pathophysiology, Clinical Patterns, and Therapeutic Challenges of Intractable and Severe Forms.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo examine volumetric magnetic resonance imaging (vMRI) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), compared to multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and healthy controls (HC).
methodsStandardized vMRI in MOGAD were compared to age, sex, and disease duration matched MS (5:1), and non-matched NMOSD and HC, in mixed linear models with time and group interactions. Disability assessments included; patient determined disease steps (PDDS), manual dexterity (MDT), walking speed (WST), processing speed (PST), and contrast sensitivity tests (CST). Correlations between vMRI and disability in MOGAD were examined.
resultsA total of 293 patients were included; 32 MOGAD, 160 MS, 49 NMOSD, and 52 HC. MOGAD had a faster rate of volume loss in all brain regions compared to HC (p < 0.05). At baseline, MOGAD had preserved thalamic (0.000507, p = 0.005), caudate (0.000287, p = 0.004), and putamen (0.000341, p = 0.007) fractions than MS. Longitudinally, MOGAD had increased lateral ventricle fraction (LVF) (-0.000645, p = 0.032), but less hippocampal (0.000031, p = 0.044) and upper cervical cord area (UCCA) loss (1.482887, p = 0.005), compared to NMOSD. MOGAD had increased LVF (0.00529, p < 0.001), but less UCCA loss (0.538656, p = 0.042) longitudinally compared to MS. Among MOGAD, UCCA was associated with PDDS (-0.72, p = 0.004) and CST (0.60, p = 0.014). Whole brain fraction (WBF) was associated with PDDS (-0.66, p = 0.01) and PST (0.52, p = 0.019). LVF was associated with PDDS (0.78, p < 0.001).
interpretationMOGAD showed longitudinal brain volume loss compared to HC. Deep gray matter was relatively preserved compared to MS, while MS and NMOSD had greater UCCA loss, indicating regional differences in atrophy. Despite less overall atrophy, volume loss in MOGAD was associated with disability. ANN NEUROL 2025;98:1044-1056.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.